Key result
This commentary highlights the clinical challenge and lack of robust evidence for using oral anticoagulants to prevent stroke in patients with atrial fibrillation and prior intracerebral haemorrhage.
Answers are grounded in this paper and cite their sources.
This commentary highlights the clinical challenge and lack of robust evidence regarding the use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracerebral haemorrhage.
This invited commentary refers to ‘Patients’ views on stroke prevention for atrial fibrillation after an intracerebral haemorrhage: a qualitative study’ by E. Ivany et al., https://doi.org/10.1093/eurjcn/zvae177. Most medical professional societies worldwide recommend that patients with atrial fibrillation (AF) receive oral anticoagulation (OAC) for stroke prevention, including the European Society of Cardiology (ESC).1 These recommendations are endorsed by other cardiovascular societies across the globe, including the American College of Cardiology (ACC) and the American Heart Association (AHA).2 However, OAC use to increases the risk of bleeding and haemorrhagic events, including intracerebral haemorrhage (ICH). Validated risk models (i.e. CHA2DS2-VASc,3 ATRIA,4 GARFIELD,5 and others6) have been developed, refined, and improved to include a more thorough assessment of the factors contributing to likelihood of bleeding or thromboembolic events and inform clinical decision-making. While in most cases the benefits of OAC outweigh the risks, the decision-making process becomes more challenging in the context of a patient with AF and also a history of ICH, due to increased bleeding risk. There are a paucity of studies to support making such clinical decisions; what has been done is in relatively modest sample sizes.7 The existing body of evidence is less robust than in uncomplicated AF and largely points to equivocal results for OAC use after ICH (though the risk is greatly decreased for OAC use in the prevention of ischaemic stroke).7 Clinicians may struggle to weigh relative risk on whether and when to restart OAC following ICH, while simultaneously taking other aspects of the patient medical history and preferences into account.2
No takes yet. Share an insight, caveat, or question.
Ansley Grimes Stanfill (2025) conducted an editorial in Atrial fibrillation with a history of intracerebral haemorrhage. Oral anticoagulants was evaluated. This commentary highlights the clinical challenge and lack of robust evidence for using oral anticoagulants to prevent stroke in patients with atrial fibrillation and prior intracerebral haemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: